Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for neutropenia in glycogen storage disease type Ib
2021-000580-78Phase 2Active
- Sponsor
- Children's Memorial Health Institute
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in glycogen storage disease type 1b, sponsored by Children's Memorial Health Institute. Primary endpoint: Safety and tolerability of empagliflozin. Started Apr 2021; status: active.
02
Drugs
empagliflozin
03
Conditions
glycogen storage disease type 1b
Beyond the preview
Go deeper on 2021-000580-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000580-78.